Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35834226

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
JAMA Oncol
Publication date
2022 Sep 1
First author
Katz MHG

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    JAMA Oncol. 2022 Sep 1;8(9):1257-1259. doi: 10.1001/jamaoncol.2022.2309.
    note
    Source null
    related pmid
    35834246
    relationship
    Comment in
  2. citation
    JAMA Oncol. 2023 Feb 1;9(2):275-276. doi: 10.1001/jamaoncol.2022.6138.
    note
    Source null
    related pmid
    36454556
    relationship
    Comment in
  3. citation
    JAMA Oncol. 2023 Feb 1;9(2):276-277. doi: 10.1001/jamaoncol.2022.6141.
    note
    Source null
    related pmid
    36454557
    relationship
    Comment in
  4. citation
    JAMA Oncol. 2023 Feb 1;9(2):275. doi: 10.1001/jamaoncol.2022.6135.
    note
    Source null
    related pmid
    36454560
    relationship
    Comment in
  5. citation
    JAMA Oncol. 2023 Feb 1;9(2):277. doi: 10.1001/jamaoncol.2022.6144.
    note
    Source null
    related pmid
    36454584
    relationship
    Comment in
  6. citation
    Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):545-552. doi: 10.1016/j.ijrobp.2022.10.022.
    note
    Source null
    related pmid
    36725162
    relationship
    Comment in

Authors and identifiers

  1. name
    Katz MHG
    type
    Author
  2. name
    Shi Q
    type
    Author
  3. name
    Meyers J
    type
    Author
  4. name
    Herman JM
    type
    Author
  5. name
    Chuong M
    type
    Author
  6. name
    Wolpin BM
    type
    Author
  7. name
    Ahmad S
    type
    Author
  8. name
    Marsh R
    type
    Author
  9. name
    Schwartz L
    type
    Author
  10. name
    Behr S
    type
    Author
  11. name
    Frankel WL
    type
    Author
  12. name
    Collisson E
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Katz MHG
    type
    Author
  2. name
    Shi Q
    type
    Author
  3. name
    Meyers J
    type
    Author
  4. name
    Herman JM
    type
    Author
  5. name
    Chuong M
    type
    Author
  6. name
    Wolpin BM
    type
    Author
  7. name
    Ahmad S
    type
    Author
  8. name
    Marsh R
    type
    Author
  9. name
    Schwartz L
    type
    Author
  10. name
    Behr S
    type
    Author
  11. name
    Frankel WL
    type
    Author
  12. name
    Collisson E
    type
    Author
bibliography ids
  1. nci-bib-0a602226828a45c2aaf5aa14
book metadata
content sha256
306e96eedac7971b360f645e759f2205dd5b96ba84ea67cc33385fc371f5ae2b
document type
citation
dois
  1. 10.1001/jamaoncol.2022.2319
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35834226
immutable id
pubmed:35834226@306e96eedac7971b360f645e759f2205dd5b96ba84ea67cc33385fc371f5ae2b
journal
abbreviation
JAMA Oncol
issn electronic
2374-2445
issn print
2374-2437
issue
9
name
JAMA oncology
nlm unique id
101652861
pages
1263-1270
volume
8
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    JAMA Oncol. 2022 Sep 1;8(9):1257-1259. doi: 10.1001/jamaoncol.2022.2309.
    note
    Source null
    related pmid
    35834246
    relationship
    Comment in
  2. citation
    JAMA Oncol. 2023 Feb 1;9(2):275-276. doi: 10.1001/jamaoncol.2022.6138.
    note
    Source null
    related pmid
    36454556
    relationship
    Comment in
  3. citation
    JAMA Oncol. 2023 Feb 1;9(2):276-277. doi: 10.1001/jamaoncol.2022.6141.
    note
    Source null
    related pmid
    36454557
    relationship
    Comment in
  4. citation
    JAMA Oncol. 2023 Feb 1;9(2):275. doi: 10.1001/jamaoncol.2022.6135.
    note
    Source null
    related pmid
    36454560
    relationship
    Comment in
  5. citation
    JAMA Oncol. 2023 Feb 1;9(2):277. doi: 10.1001/jamaoncol.2022.6144.
    note
    Source null
    related pmid
    36454584
    relationship
    Comment in
  6. citation
    Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):545-552. doi: 10.1016/j.ijrobp.2022.10.022.
    note
    Source null
    related pmid
    36725162
    relationship
    Comment in
outcomes validated
false
pmid
35834226
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
3c4cf904427b75605de488ddef425d75d615583c28e8c56c024555a0645b6c07
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Sep 1
precision
day
year
2022
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35834226/
title
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.

Preserved source evidence · Not medical advice